

Aeglea BioTherapeutics, Inc.  
Form 8-K  
February 16, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2017

AEGLEA BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37722	46-4312787
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

901 S. MoPac Expressway

Barton Oaks Plaza One

Suite 250

Austin, TX	78746
(Address of principal executive offices)	(Zip Code)

(512) 942-2935

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
Item 5.02. Compensatory Arrangements of Certain Officers.

On February 15, 2017, the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) appointed Suzanne Bruhn as a Class I director, effective as of the same date.

Ms. Bruhn will receive an annual cash retainer of \$35,000 per year in accordance with the Company’s existing compensation policy for non-employee directors. In addition, the Board granted to Ms. Bruhn, effective February 15, 2017, a stock option to purchase 82,000 shares of common stock at an exercise price of \$5.04 per share, which will vest monthly over three years, subject to Ms. Bruhn’s continued service to the Company.

The Company has entered into its standard form of indemnification agreement with Ms. Bruhn. A form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 14, 2015.

There is no arrangement or understanding with any person pursuant to which Ms. Bruhn was appointed as a member of the Board, and Ms. Bruhn does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AEGLEA  
BIOTHERAPEUTICS,  
INC.

Date: February 16, 2017    By: /s/ Charles N. York II  
Charles N. York II  
Chief Financial Officer